Tocilizumab for the treatment of COVID-19.
Robert FlisiakMarta Flisiak-JackiewiczPiotr RzymskiDorota Zarębska-MichalukPublished in: Expert review of anti-infective therapy (2023)
The criteria for optimizing tocilizumab therapy in COVID-19 still need to be established. They are also important considering the existing risks of future zoonotic spillovers and epidemics that may trigger hyperinflammation that could be efficiently blocked. The experience gained with tocilizumab shall be perceived as preparedness for future challenges.
Keyphrases
- rheumatoid arthritis
- coronavirus disease
- sars cov
- juvenile idiopathic arthritis
- rheumatoid arthritis patients
- current status
- public health
- disease activity
- depressive symptoms
- physical activity
- social support
- mental health
- respiratory syndrome coronavirus
- infectious diseases
- human health
- stem cells
- risk assessment
- bone marrow